Metabolic Health, Not PMOS, Drives Dementia Risk
A review of 26 studies finds metabolic comorbidities, rather than polycystic ovary syndrome itself, appear to account for any increased Alzheimer's and dementia risk.
Updated on Nov. 5, 2026 in Alzheimer’s
Live Poll
Do you trust your doctor to explain long-term brain health risks clearly?
A review published in the Journal of the Endocrine Society concludes that metabolic comorbidities, not premenstrual ovarian syndrome (PMOS) itself, drive any increased risk of Alzheimer's disease and dementia. The analysis integrated epidemiological, brain imaging, and biomarker data from 26 studies.
Why it matters
PMOS affects an estimated 10-15% of reproductive-aged women globally and has been linked to diabetes, heart disease, and depression. Identifying metabolic health as the driver of brain risk could shift how clinicians monitor affected patients.
The review pooled 26 studies covering a condition affecting 10-15% of reproductive-aged women worldwide, with women over 65 facing a two- to three-fold higher Alzheimer's risk than men. Whether PMOS independently raises dementia risk remains unresolved, as a retrospective study and a prospective UK Biobank study reached opposing conclusions.
The players
University of Alabama at Birmingham
The institution of the review's corresponding author, a public research university known for its medical and biomedical research programs.
Journal of the Endocrine Society
A peer-reviewed scientific journal published by the Endocrine Society that covers research on hormones and endocrine physiology.
The details
Researchers searched PubMed from its inception through October 2025, combining PMOS terms with Alzheimer's, dementia, hippocampus, and cognitive performance keywords, then paired insulin resistance, chronic inflammation, oxidative stress, and gut microbiome shifts with neurological terms. The authors concluded that brain-related risks appear tied to metabolic health rather than to PMOS on its own.
Timeline
October 2025: End date of the PubMed literature search.
2026: Review published in the Journal of the Endocrine Society.
Health Landscape
The UK Biobank prospective cohort, which has tracked health outcomes in a large British population, found no direct PMOS-dementia link after adjusting for body mass index, a result this review's metabolic-driver conclusion extends. Competing retrospective findings of higher dementia prevalence suggest the field still lacks the lifespan-spanning cohorts the authors call for.
Women with PMOS may want to discuss metabolic markers such as blood sugar, insulin resistance, and cardiovascular risk with their clinicians, since the review ties brain-related risk to these factors. Routine screening for metabolic health may matter more than the PMOS diagnosis alone.
The takeaway
Managing metabolic health, including blood sugar and weight, appears to be the most actionable lever for brain health in women with PMOS. Larger long-term studies will be needed before the link is considered settled.
Further reading
Explore more on Alzheimer’s research and risk factors in women's brain health.
Live Poll
Do you trust your doctor to explain long-term brain health risks clearly?
